Last reviewed · How we verify
Farxiga
At a glance
| Generic name | Farxiga |
|---|---|
| Sponsor | AstraZeneca |
| Target | Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Chronic heart failure
- Chronic kidney disease
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
- Female genital mycotic infections
- Nasopharyngitis
- Urinary tract infections
- Back pain
- Increased urination
- Male genital mycotic infections
Serious adverse events
- Severe hypoglycemia
- Diabetic ketoacidosis (DKA)
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) (PHASE3)
- Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy (NA)
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. (NA)
- The Effect of Dapagliflozin on Myocardial Strain in Patients With Acute Heart Failure (NA)
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Farxiga CI brief — competitive landscape report
- Farxiga updates RSS · CI watch RSS
- AstraZeneca portfolio CI